|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metastatic prostate cancer remains incurable, why?显示文摘Metastatic prostate cancer patients present in two waysdwith already disseminated disease at the time of presentation or with disease recurrence after definitive local therapy.Androgen deprivation therapy is given as the most effective initial treatment to patients.However,after the initial response,almost all patients will eventually progress despite the low levels of testosterone.Disease at this stage is termed castration resistant prostate cancer(CRPC).Before 2010,the taxane docetaxel was the first and only life prolonging agent for metastatic CRPC(mCRPC).The last decade has witnessed robust progress in CRPC therapeutics development.Abiraterone,enzalutamide,apalutamide and sipuleucel-T have been evaluated as first-and second-line agents in mCRPC patients,while cabazitaxel was approved as a second-line treatment.Radium-223 dichloride was approved in symptomatic patients with bone metastases and no known visceral metastases pre-and post-docetaxel.However,despite significant advances,mCRPC remains a lethal disease.Both primary and acquired resistance have been observed in CRPC patients treated by these new agents.It could be solely cell intrinsic or it is possible that the clonal heterogeneity in treated tumors may result from the adaptive responses to the selective pressures within the tumor microenvironment.The aim of this review is to list current treatment agents of CRPC and summarize recent findings in therapeutic resistance mechanisms. | Liang Dong Richard C.Zieren Wei Xue Theo M.de Reijke Kenneth J.Pienta | 2019 | Asian Journal of Urology2019，6，1： | 9 |
| 2 | Rectal squamous cell carcinoma 11 years after brachytherapy for carcinoma of the prostare显示文摘 | Yurdakal G de Reijke T M Blank L E | 2003 | J Urol2003，169，： | 1 |
| 3 | The Prostate Cancer gene 3 assay~ indications for use in clinical practice显示文摘 | SCHILLING D DE REIJKE T TOMBAL B | 2010 | BJU Int2010，105，4： | 1 |
| 4 | 4002 ORAL Six months versus three years concomitant and adjuvant hormonal treatment with external beam irradiation for locally advanced prostate cancer: Results of the EORTC randomized Phase Ⅲ trial 22961显示文摘 | Michel B van Tienhoven De Reijke | 2007 | European Journal of Cancer Supplements2007，5，4： | 1 |
| 5 | The relationship between the serum level of prostate specific antigen and CT scans in the Staging of primary cancinoma of the prostate显示文摘 | Hulshof MC de Reijke TM | 1998 | Ned Tijdschr Geneeskd1998，142，： | 1 |
| 6 | Duration of an- drogen suppression in the treatment of prostate cancer显示文摘 | Bolla M de Reijke TM Van Tienhoven G | 2009 | N Engl J Med2009，360，24： | 1 |
| 7 | Stron-tium (89) chloride versus palliative local field radiothera-py in patients with hormonal escaped prostate cancer: aphase M study of the European Organisation for Researchand Treatment of Cancer, Genitourinary Group显示文摘 | Oosterhof GO Roberts JT de Reijke TM | 2003 | Euri7ral2003，44，5： | 1 |
| 8 | Standardization of def- initions in focal therapy of prostate cancer: report from a Delphi con- sensus project显示文摘 | Postema AW De Reijke TM Ukimura O | 2016 | World J Urol2016，18，21： | 1 |
| 9 | EORTCGU group expert opinion on metastatic renal cell cancer显示文摘 | de Reijke TM Bellmunt J van Poppel H | 2009 | Eur J Cancer2009，45，5： | 1 |
| 10 | Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value 显示文摘 | de Reijke TM De Boer EC Kurth KH | 1996 | J Urol1996，155，2： | 1 |
| 11 | Kinetics of prostate-specific antigen after manipulation of the prostate 显示文摘 | Bossens M M van Straalen J P De Reijke T M | 1995 | Eur J Cancer1995，31，5： | 1 |
| 12 | The Prostate Cancer gene 3 assay indications for use in clinical practice 显示文摘 | Schilling D De Reijke T TombaI B | 2010 | BJUinternational2010，105，4： | 1 |
| 13 | Best practice in the treat- ment of nonmuscle invasive bladder cancer 显示文摘 | Anastasiadis A de Reijke T M | 2012 | Ther Adv Uro12012，4，1： | 1 |
| 14 | Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer显示文摘 | Hendricksen K Cornel EB de Reijke TM | 2012 | J Urol2012，187，4： | 1 |
| 15 | The prostate cancer gene 3 assay: indications for use in clinical practice显示文摘 | Schilling D de Reijke T Tombal B | 2010 | BJU Int2010，105，： | 1 |
| 16 | New developments in castrate-resistant prostate cancer 显示文摘 | Shore N Mason M de Reijke T M | 2012 | BJU Int2012，109，6： | 1 |
| 17 | Duration of an- drogen suppression in the treatment of prostate cancer 显示文摘 | Bolla M de Reijke TM Van Pilepieh MV | 2009 | N E ngl J M ed2009，360，24： | 1 |
| 18 | Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residualtumour rate显示文摘 | Cauberg E C Mamoulakis C de la Rosette J J de Reijke T M | 2011 | World J Urol2011，29，： | 1 |
| 19 | Bacillus Calmette-Guerin versus epirubicin for primary,secondary or concurrent carcinoma in situ of the bladder:results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase Ⅲ Trial (30906)显示文摘 | de Reijke TM Kurth KH Sylvester RJ | 2005 | J Urol2005，173，2： | 1 |
| 20 | Dabhoiwala NFBrachytherapy with transperineal (125)Iodine seed prostate cancer显示文摘 | Blank LE Gonzalez D de Reijke TM | | 0，，03： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员